

## OBJECTIVES/AIMS

To explore the connection between cerebrospinal fluid (CSF) inflammatory markers present at diagnosis and subsequent retinal layer thinning.

## MATERIALS

Forty-eight patients from a single referral centre (the University of Verona) affected by RRMS, who did not have a clinical episode of optic neuritis or other ocular pathologies were included in the study.

Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany, dilated pupils, eye tracking) was employed. We use a macular volume scan (25°×30°, 61 B-scans, 768 A-scans per B-scan, 12≤ART≤15) to quantify the retinal volume. Data on average pRNFL, superior sector, temporal sector, inferior sector, nasal sector (um), GCL and IPL (mm3) were collected.

For analysis, the OCT values of the right eye were included. We measured CSF levels of 68 inflammatory molecules.

## METHODS

For measurement of the peripapillary retinal nerve fibre layer thickness (RNFL), we used a ring scan around the optic nerve head (12°, 1536 A-scans, 16≤ Automatic Real-Time (ART) averaging ≤100) using the device-internal segmentation module 6.0.14.0. Macular retinal volume was segmented to obtain data on single layers, in particular ganglion cell layer (GCL) and inner plexiform layer (IPL) volume were obtained. Inflammatory molecules were evaluated with multiplex technology at the time of diagnosis.

## RESULTS



Of the 48 patients enrolled, 35 (73%) were female. The median EDSS was 3 (range 0-4), and the mean age was 37.5 ± 14 years. A lower GCL was significantly associated with higher levels of inflammatory markers, including MMP1 (r = -0.424, p = 0.035), Osteopontin (r = -0.322, p = 0.048), and CCL3 (r = -0.334, p = 0.040). Furthermore, a trend towards a negative correlation was observed with several markers of smoldering disease activity, such as sCD163 (r = -0.217) and Chitinase3-like1 (r = -0.265). Similarly, a lower IPL was associated with increased values of MMP1 (r = -0.540, p = 0.005), IFNα2 (r = -0.501, p = 0.041), and CXCL2 (r = -0.439, p = 0.036), and slightly associated with LIGHT levels (r = -0.378).

## DISCUSSION

This study investigated the relationship between retinal structural integrity (assessed by OCT) and intrathecal inflammatory markers in a cohort of early-stage Relapsing-Remitting Multiple Sclerosis (RRMS) patients. Our results suggest that OCT parameters, performed at diagnosis, could serve as reliable early biomarkers of intrathecal inflammatory processes in RRMS.

## CONCLUSIONS

Diagnostic OCT may help as a reliable marker for intrathecal inflammation occurring in early multiple sclerosis.



## REFERENCES

- Roberta Magliozzi, Owain W. Howell, Richard Nicholas, Carolina Cruciani, Marco Castellaro, Chiara Romualdi, Stefania Rossi, Marco Pitteri, Maria Donata Benedetti, Alberto Gajofatto, Francesca B Pizzini, Stefania Montemezzi, Sarah Rasia, Ruggero Capra, Alessandra Bertoldo, Francesco Facchiano, Salvatore Monaco, Richard Reynolds, Massimiliano Calabrese - Inflammatory intrathecal profiles and cortical damage in multiple sclerosis - Annals of Neurology - 2018 - 83 (4) - 739
- Ting - Yi Lin, Seyedamirhosein Motamedi, Susanna Asseyer, Claudia Chien, Shiv Saidha, Peter A. Calabresi, Kathryn C. Fitzgerald, Sara Samadzadeh, Pablo Villoslada, Sara Llufrui, Ari J. Green, Jana Lizrova Preiningerova, Axel Petzold, Letizia Leocani, Elena Garcia - Martin, Celia Oreja - Guevara, Olivier Outterlyck, Patrick Vermersch, Laura J. Balcer, Rachel Kenney, Philipp Albrecht, Orhan Aktas, Fiona Costello, Jette Frederiksen, Antonio Uccelli, Maria Cellerino, Elliot M. Frohman, Teresa C. Froh Natascha Schurz, Lydia Sariaslani, Patrick Altmann, Fritz Leutmezer, Christoph Mitsch, Berthold Pemp, Paulus Rommer, Tobias Zrzavy, Thomas Berger, Gabriel Bsteh - Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real - World Multiple Sclerosis Cohort - Eye and Brain - 2021 - 13

## DISCLOSURES

Eugenio Peluso: nothing to disclose; Luca Polinelli: nothing to disclose; Stefano Ziccardi: nothing to disclose; Agnese Tamanti: received research support from Merck; Valentina Camera: received research grant from European Charcot Foundation, received support for scientific meetings from Biogen, Janssen, Novartis, BMS, Roche, Alexion and speaking honoraria from Novartis and Alexion; Francesca Bosello: nothing to disclose; Massimiliano Calabrese: received speaker honoraria from Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, and Roche and received research support from the Progressive MS Alliance, Italian Minister of Health, the Novartis Pharma, Roche, Bristol Myers Squibb and Merck Serono; Damiano Marastoni: received research support and/or honoraria for speaking and funds for travel from Roche, Sanofi-Genzyme, Merck-Serono, Biogen Idec, and Novartis and receives research support from Italian Minister of Health;



**55° CONGRESSO  
SOCIETÀ ITALIANA  
DI NEUROLOGIA**